Table 3.
Concordance statistics (κ) for indicated use of individual immunosuppressive drugsa
| Drug | OPTM/MR | ±30 D of Follow-up Date Window for Claims Ascertainment
|
±90 D of Follow-up Date Window for Claims Ascertainment
|
||
|---|---|---|---|---|---|
| OPTN/CLM | MR/CLM | OPTN/CLM | MR/CLM | ||
| Cyclosporine | |||||
| discharge | 0.81 (0.69 to 0.92) | 0.81 (0.63 to 0.99) | 0.88 (0.73 to 1.00) | 0.90 (0.76 to 1.00) | 0.94 (0.82 to 1.00) |
| 6 mo | 0.82 (0.71 to 0.94) | 0.59 (0.35 to 0.82) | 0.74 (0.55 to 0.93) | 0.82 (0.62 to 1.00) | 0.91 (0.78 to 1.00) |
| 1 yr | 0.87 (0.78 to 0.96) | 0.91 (0.79 to 1.00) | 0.92 (0.81 to 1.00) | 0.96 (0.87 to 1.00) | 1.00 (1.00 to 1.00) |
| Tacrolimus | |||||
| discharge | 0.88 (0.78 to 0.97) | 0.90 (0.76 to 1.00) | 1.00 (1.00 to 1.00) | 0.90 (0.76 to 1.00) | 1.00 (1.00 to 1.00) |
| 6 mo | 0.86 (0.76 to 0.97) | 0.80 (0.59 to 1.00) | 0.84 (0.66 to 1.00) | 0.87 (0.70 to 1.00) | 0.90 (0.75 to 1.00) |
| 1 yr | 0.94 (0.88 to 1.00) | 1.00 (1.00 to 1.00) | 1.00 (1.00 to 1.00) | 1.00 (1.00 to 1.00) | 1.00 (1.00 to 1.00) |
| MMF | |||||
| discharge | 0.69 (0.57 to 0.81) | 0.64 (0.44 to 0.83) | 0.96 (0.87 to 1.00) | 0.67 (0.49 to 0.86) | 1.00 (1.00 to 1.00) |
| 6 mo | 0.81 (0.70 to 0.92) | 0.74 (0.52 to 0.95) | 0.64 (0.43 to 0.85) | 0.80 (0.60 to 0.99) | 0.73 (0.54 to 0.92) |
| 1 yr | 0.90 (0.82 to 0.98) | 0.79 (0.62 to 0.96) | 0.85 (0.71 to 0.99) | 0.84 (0.68 to 0.99) | 0.89 (0.77 to 1.00 |
| Azathioprine | |||||
| discharge | 0.62 (0.49 to 0.75) | 0.38 (0.16 to 0.60) | 0.84 (0.70 to 0.99) | 0.48 (0.27 to 0.70) | 0.92 (0.81 to 1.00) |
| 6 mo | 0.84 (0.73 to 0.94) | 0.80 (0.62 to 0.99) | 0.74 (0.55 to 0.92) | 0.85 (0.69 to 1.00) | 0.93 (0.83 to 1.00) |
| 1 yr | 0.85 (0.75 to 0.94) | 0.73 (0.54 to 0.91) | 0.81 (0.67 to 0.95) | 0.85 (0.70 to 0.99) | 0.91 (0.80 to 1.00) |
| Sirolimus | |||||
| discharge | b | b | b | b | b |
| 6 mo | 1.00 (1.00 to 1.00) | b | b | b | b |
| 1 yr | 1.00 (1.00 to 1.00) | b | b | b | b |
a
Analytic samples were defined by the availability of maintenance immunosuppression information in the data sources under comparison at the study time points of interest. κ grading criteria as follows: κ < 0.20, poor; κ = 0.20 to 0.39, fair; κ = 0.40 to 0.59, moderate; κ = 0.60 to 0.79, very good; κ > 0.80, excellent (17).
b
κ not calculable because of absence of any reported drug-specific use in one or both comparison groups.